Last reviewed · How we verify
Treatment Choice
Treatment Choice is a Small molecule inhibitor Small molecule drug developed by Astex Pharmaceuticals, Inc.. It is currently FDA-approved.
Treatment Choice is a study that combines low-dose radiotherapy (LDRT) with the medication Pucotenlimab and standard therapy for advanced pancreatic cancer. Pucotenlimab is a small molecule medication, classified as a modality, used in the Treatment Choice study for pancreatic cancer treatment.
At a glance
| Generic name | Treatment Choice |
|---|---|
| Sponsor | Astex Pharmaceuticals, Inc. |
| Drug class | Small molecule inhibitor |
| Target | DNA repair enzyme |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Key clinical trials
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (PHASE1)
- HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor (PHASE1, PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (PHASE1, PHASE2)
- Establishing of the Inter-rater Reliability and Variability of Selected Standardized Tests Performed in Czech Language
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment Choice CI brief — competitive landscape report
- Treatment Choice updates RSS · CI watch RSS
- Astex Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Treatment Choice
What is Treatment Choice?
Who makes Treatment Choice?
What drug class is Treatment Choice in?
What development phase is Treatment Choice in?
What does Treatment Choice target?
Related
- Drug class: All Small molecule inhibitor drugs
- Target: All drugs targeting DNA repair enzyme
- Manufacturer: Astex Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing